CHM 0301 / Chimeric Therap, Case Western Reserve University - LARVOL DELTA

Chimeric Reveals Encouraging In-Vitro Data for CHM 0301 Platform (Mirage News) - "Cell therapy company Chimeric Therapeutics...has reported positive in-vitro data for CHM 0301, its next-generation armoured natural killer (NK) cell platform...CHM 0301 cells express a dominant-negative TGFβ receptor molecule on the cell surface and secrete the immunostimulatory cytokine interleukin 15 (IL-15)....The company said that when evaluated in in-vitro models of human AML and CRC, CHM 0301 demonstrated significant enhancement of TGFβ resistance and potency compared to first-generation CHM 0201 cells."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology